Supernus (SUPN) drops 2.81% to close at $ 26.59 on September 10

Supernus Pharmaceuticals Inc (NASDAQ: SUPN), a Rockville, Md., Company, closed at $ 26.59 on Friday after losing $ 0.77 (2.81%) on volume of 318,698 shares. The stock ranged from a high of $ 27.80 to a low of $ 26.56, while Supernus’ market cap now stands at $ 1,413,149,056.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a pharmaceutical company specializing in the development and commercialization of products for the treatment of diseases of the central nervous system (CNS). The Company markets Trokendi XR® (prolonged-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (oxcarbazepine sustained release) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and the treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunct to levodopa / carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to seize major market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.

Visit the Supernus Pharmaceuticals Inc profile for more information.

About the Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, as well as the listing of stocks and options. The Nasdaq is the world’s largest stock exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information about Supernus Pharmaceuticals Inc and keep up with the latest company updates, you can visit the company profile page here: Supernus Pharmaceuticals Inc. Profile For more financial market information, no. be sure to visit Equities News. Also, don’t forget to sign up for the Daily Fix to get the best stories delivered to your inbox 5 days a week.

Sources: The chart is provided by TradingView on the basis of prices delayed by 15 minutes. All other data is provided by IEX Cloud as of 8:05 p.m. ET on the day of publication.

The views and opinions expressed in this article are those of the authors and do not represent the views of Readers should not take the author’s statements as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please visit:

Unemployment claims drop to 310,000 – lowest in nearly 18 months

200 Westerners on a Qatar Airways flight from Kabul

Pennsylvania Republican lawmakers launch election integrity probe

President Biden and Congressional Democrats push for civilian climate body

Biden administration to unveil plan to cut prescription drug prices in Medicare

Hurricane Ida toll in Louisiana rises to 26

Minorities and children suffered increased hunger in 2020 despite federal pandemic aid

Australia’s High Court Holds Media Companies Responsible for Third-Party Comments on Their Facebook Pages

About Michael Bill

Check Also

Epilepsy Drugs Market 2022 Industry Outlook and Key Players are Abbott Laboratories, GlaxoSmithKline Plc, UCB, Cephalon – Instant Interview recently declared the distribution of the new report entitled Global epilepsy drugs market from …

Leave a Reply

Your email address will not be published.